DRG Market Assessment reports

The number of total prevalent cases of SAD in the countries under study will increase by 7% from 21 million to 23 million in 20 years. Of the countries considered in this analysis, the total…

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…

CIAS (e.g., impaired attention / vigilance, memory, and/or executive function) negatively impacts patients’ daily activities, occupational and social functioning, and adherence to antipsychotic…

In the United States, atypical antipsychotics available in oral and injectable (e.g., long-acting injectable [LAI]) formulations are the mainstay of schizophrenia treatment. However, the dearth of…

Post-traumatic stress disorder (PTSD) is a chronic psychiatric condition that may emerge after a person experiences a traumatic event or series of events. Multiple guidelines recommend first…

Clarivate Epidemiology’s coverage of generalized anxiety disorder (GAD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States,…

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for…

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for…

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for…

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for…